It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its treatment that tunes gene activity within the body. Why it matters: The ...

Major investors are betting that a Durham company has a potential cure for hepatitis B. STORY HIGHLIGHTS Tune Therapeutics raised $175 million for disease treatment development. The funding ...

In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years. Tune ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

DURHAM, N.C. & SEATTLE, January 13, 2025--(BUSINESS WIRE)--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise ...

Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced ... offices in Seattle and at the downtown Durham ID building. Series A and B are the two ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

The Durham ID building in downtown Durham, NC holds the North Carolina office of Tune Therapeutics, a growing biotech startup moving into trials. Brian Gordon Launched from a Duke University lab ...